Home › Funds › WESTFIELD CAPITAL MANAGEMENT CO LP › ASND

WESTFIELD CAPITAL MANAGEMENT CO LP position in ASND

ASCENDIS PHARMA A/S · Health Care

WESTFIELD CAPITAL MANAGEMENT CO LP reported holding 5,125,027 shares of ASND (ASCENDIS PHARMA A/S) in its Q3 2026 13F filing — a position valued at US$1.17B, representing 3.82% of its reported portfolio and ranking #3 among its reported holdings. WESTFIELD CAPITAL MANAGEMENT CO LP has disclosed ASND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)5.13M sh
Reported value held$1.17B
Portfolio Weight3.82%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How WESTFIELD CAPITAL MANAGEMENT CO LP's ASND position evolved

WESTFIELD CAPITAL MANAGEMENT CO LP first disclosed a stake in ASND in Q3 2023 at 3,802,177 shares (US$356.0M). The position peaked in Q2 2026 at 4,798,267 shares, worth US$1.28B. Across 13 filings, WESTFIELD CAPITAL MANAGEMENT CO LP increased the stake 6 time(s), trimmed it 5 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 5,125,027 shares valued at US$1.17B — an increase of 326,760 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 3.80M $356.04M New
Q4 2023 4.03M $507.66M Add
Q1 2024 4.08M $616.05M Add
Q2 2024 4.96M $676.83M Add
Q3 2024 5.13M $766.52M Add
Q4 2024 5.53M $761.07M Add
Q1 2025 5.48M $854.00M Reduce
Q2 2025 5.45M $940.91M Reduce
Q3 2025 5.26M $1.05B Reduce
Q4 2025 5.19M $1.11B Reduce
Q1 2026 4.81M $1.10B Reduce
Q2 2026 4.80M $1.28B Hold
Q3 2026 5.13M $1.17B Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ASND and 13F data

ASND (ASCENDIS PHARMA A/S) is a Health Care company. 36 other funds we track also report a position in ASND — the largest reported positions include RA CAPITAL MANAGEMENT, L.P. (US$2.74B), T. Rowe Price Investment Management, Inc. (US$1.80B), Avoro Capital Advisors LLC (US$1.36B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ASND

All ASND fund holders →

FAQ

How long has WESTFIELD CAPITAL MANAGEMENT CO LP held ASND?

WESTFIELD CAPITAL MANAGEMENT CO LP has disclosed ASND holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is WESTFIELD CAPITAL MANAGEMENT CO LP's current position in ASND?

As of Q3 2026, WESTFIELD CAPITAL MANAGEMENT CO LP holds 5.13M shares of ASND (ASCENDIS PHARMA A/S), valued at $1.17B, representing 3.82% of its reported portfolio and ranking #3.

Has WESTFIELD CAPITAL MANAGEMENT CO LP been buying or selling ASND?

In the latest 13F filing (Q3 2026), WESTFIELD CAPITAL MANAGEMENT CO LP increased its position in ASND. The position peaked in Q2 2026 at 4.80M shares.

Which other funds hold ASND?

Other major institutional holders of ASND include RA CAPITAL MANAGEMENT, L.P., T. Rowe Price Investment Management, Inc., Avoro Capital Advisors LLC, among 36 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.